Anixa Biosciences (NASDAQ:ANIX) Stock Rating Reaffirmed by HC Wainwright

Anixa Biosciences (NASDAQ:ANIXGet Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $12.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 246.82% from the company’s current price. HC Wainwright also issued estimates for Anixa Biosciences’ Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS and Q4 2025 earnings at ($0.11) EPS.

Anixa Biosciences Trading Down 6.2 %

Shares of Anixa Biosciences stock opened at $3.46 on Thursday. The stock’s fifty day moving average price is $4.03 and its 200-day moving average price is $3.66. Anixa Biosciences has a 12 month low of $2.75 and a 12 month high of $6.45. The firm has a market cap of $110.37 million, a P/E ratio of -10.18 and a beta of 0.85.

Anixa Biosciences (NASDAQ:ANIXGet Free Report) last posted its earnings results on Tuesday, January 16th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Analysts forecast that Anixa Biosciences will post -0.37 earnings per share for the current year.

Insider Transactions at Anixa Biosciences

In other news, CEO Amit Kumar bought 30,000 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The stock was purchased at an average price of $3.22 per share, with a total value of $96,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 491,925 shares of the company’s stock, valued at approximately $1,583,998.50. The purchase was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Arnold M. Baskies purchased 10,000 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was bought at an average cost of $3.63 per share, with a total value of $36,300.00. Following the completion of the acquisition, the director now owns 110,000 shares of the company’s stock, valued at approximately $399,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Amit Kumar purchased 30,000 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was bought at an average cost of $3.22 per share, with a total value of $96,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 491,925 shares of the company’s stock, valued at approximately $1,583,998.50. The disclosure for this purchase can be found here. Insiders own 22.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ANIX. Mission Wealth Management LP acquired a new position in shares of Anixa Biosciences during the 3rd quarter worth approximately $1,639,000. BlackRock Inc. grew its holdings in Anixa Biosciences by 191.9% in the 3rd quarter. BlackRock Inc. now owns 297,513 shares of the company’s stock valued at $1,464,000 after buying an additional 195,603 shares in the last quarter. Susquehanna International Group LLP grew its holdings in Anixa Biosciences by 73.4% in the 1st quarter. Susquehanna International Group LLP now owns 155,784 shares of the company’s stock valued at $670,000 after buying an additional 65,961 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Anixa Biosciences in the 1st quarter valued at $266,000. Finally, International Assets Investment Management LLC lifted its stake in shares of Anixa Biosciences by 274.6% in the 4th quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock valued at $2,110,000 after purchasing an additional 39,820 shares during the last quarter. 11.78% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

Read More

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.